DSO Recapitalization Data Room (2026): What a Dental Platform Proves at Its Second Bite

Last updated: August 2026

I'm Sean Yu, co-founder of Peony. Before Peony I spent my career on the deal side, and the dental conversation I have most often now is not with a dentist selling one practice. It is with a founder or CFO who built a dental support organization to three, five, or ten million dollars of platform EBITDA and is heading into the event the whole thing was built for: the recapitalization. Their sponsors are signaling a process, or they are raising minority capital to keep going, and the question is always some version of the same thing. What do we actually have to prove, who is going to be in the room, and how is this different from selling a practice? I run Peony, a data room company serving 6,800+ customers, so I see these processes from the inside. This post is the platform-level answer.

Here is the fair part up front. A recap is where the roll-up journey exits. If you have been building a dental platform by acquiring practices, you have been running many small diligence rooms and rolling equity into your sellers along the way; a recap is the one large, multi-party room where all of that gets monetized. It is a genuinely different diligence event than a practice sale, it runs on a different room architecture, and getting the architecture wrong is expensive in a way that a single-practice mistake never is.

Quick answer. A DSO recapitalization is a platform-level capital event, not a practice sale: a sponsor-to-sponsor majority sale, a minority growth round, or a continuation vehicle, run on a roughly three-to-seven-year hold rhythm, and it is where the rollover equity from your practice acquisitions finally turns liquid. The diligence goes to the platform's machine, not one office's charts: same-store growth by acquisition vintage, integration track record, provider retention, and a clean legal structure. The room holds several competing bidders, a lender group, a quality-of-earnings firm, and counsel, none of whom can see each other, revealed in stages as the process moves. After close, the same room becomes the home for lender reporting. Run it on flat per-admin pricing (Peony Deal Team, 64 dollars per admin per month billed annually, four-admin minimum, unlimited rooms, free viewers) and a multi-party process costs the same as a single room.

What is a DSO recapitalization?

A DSO recapitalization is a platform-level capital event that resets the ownership of the support organization without selling the individual practices underneath it. It is the exit chapter of a roll-up, and it takes three common shapes. A sponsor-to-sponsor majority sale is one private-equity owner selling control of the platform to the next. A minority growth investment is a new investor buying a stake alongside the incumbents to fund the next leg of growth. A continuation structure is the current sponsor moving the platform into a new vehicle so it can keep running it past a fund's normal life. All three reset the capital stack; none of them requires the dentists in the chairs to change anything about how they practice.

The rhythm underneath all of this is a three-to-seven-year hold. A sponsor buys or builds a platform, compounds it for a few years, and then recapitalizes or sells at what it hopes is a higher multiple. That event is the mechanical reason rollover equity exists. When a DSO acquires a practice, it commonly requires the selling dentist to reinvest a slice of proceeds, typically 10 to 30 percent of deal value, into acquirer equity, which stays illiquid for roughly five to seven years and tracks the whole platform's performance rather than that one office (Deal Prospectors; Dental Wealth Partners). The recap is the moment that paper becomes cash. The equity those selling dentists rolled becomes real here, which is exactly why the practice-side DSO offer evaluation guide tells sellers to treat the second bite as a bet on the platform's next recapitalization, not as cash in hand.

It helps to make this concrete with public examples, each stated as of its announcement date because private-equity ownership on these platforms is fluid. In MB2 Dental's November 2024 recapitalization, Warburg Pincus invested about 525 million dollars as a new minority investor, valuing the company around 3.5 billion dollars and joining existing investors Charlesbank Capital Partners, which has held control since January 2021, and KKR. Smile Brands has been owned by Gryphon Investors since 2016, when Gryphon acquired it from Welsh, Carson, Anderson and Stowe; its 2023 transaction was a dividend recapitalization, not a change of ownership. Affordable Care has been controlled by Harvest Partners and PSP Investments since its June 2021 recapitalization of roughly 2.7 billion dollars, with prior owner Berkshire Partners retaining a minority rollover stake. And Heartland Dental, the largest US DSO, has been majority-owned by KKR since 2018, with Ontario Teachers' Pension Plan holding a minority position. Read every one of those as a snapshot; verify the current cap table from the primary source before you rely on it.

Why is a platform recap a different diligence event than a practice sale?

Because the buyer is institutional and the diligence goes to the platform's machine, not one office's patient charts. When a dentist sells a single practice, the buyer is testing whether that location's collections, patient base, and provider are real and transferable. When a sponsor buys a platform, the buyer is an institution testing whether the group can keep compounding after the deal closes. Those are different questions, and they pull the diligence toward completely different evidence.

Start with valuation, because it sets the stakes. Advisory bands for 2025 to 2026 put single-doctor tuck-ins in the mid-single digits of adjusted EBITDA and climb from there; platform-grade DSO groups above 5 million dollars of EBITDA are cited at roughly 10x to 12x or more (Deal Prospectors, 2026). At that multiple, a swing in defensible platform EBITDA moves enterprise value by an order of magnitude more than the same swing on a single office, so the buyer's scrutiny concentrates on the numbers that scale.

That is why platform diligence goes to the system. A buyer sampling a recap does not primarily want to read one practice's charts; it wants to know whether same-store performance is genuinely growing, whether the acquisitions that built the group were integrated and delivered the synergies underwritten, and whether the acquisition pipeline is repeatable. Buyers still sample individual practices, and the per-practice layer they test is exactly what a dental due diligence checklist and a single-practice sale data room are built to satisfy. But sampling a few offices is a control on the platform's reported numbers, not the main event. The main event is the machine.

This is also the cleanest way to see the division of labor across this lane. The dental roll-up and DSO playbook is where the platform gets built, acquisition by acquisition; this post is where that built platform gets monetized. You build the group there and you prove it here.

What does the platform have to prove?

It has to prove the machine works, at the platform level and broken out by acquisition cohort. A recap buyer is underwriting future compounding, so the evidence set is different in kind from a practice file. These are the folders a platform recap has to fill, and none of them exists in a single-practice sale.

• Same-store collections and EBITDA growth by vintage cohort. The single most important exhibit. Grouping performance by the year each practice was acquired lets a buyer separate real organic same-store growth from growth that was simply bought through acquisitions. A platform that grows only by buying is worth less than one whose acquired offices keep improving after they join.
• Add-on integration track record. For each acquisition, what was underwritten versus what was realized. Synergy realization against the model is how a buyer decides whether your integration playbook actually works or whether the deals were bought and left alone.
• Platform-level quality of earnings with add-back discipline. A rolled-up, defensible adjusted-EBITDA package. Add-backs that cannot be documented get struck, and at a platform multiple every struck dollar is amplified. The mechanics of how buyers test the number are their own subject in our quality of earnings guide; the illustrative point stands that a padded number costs far more at 10x than at 5x.
• De novo economics, if the platform builds. Ramp curves, time to breakeven, and cost per new office for platforms that grow by building rather than only buying.
• Provider retention and work-back status. Selling dentists commonly commit to multi-year work-backs, and a buyer wants the current status across the base: who is still under commitment, whose is expiring, and what retention looks like when it does. A platform whose key producers are about to roll off is a different asset than one that keeps them.
• Hygiene and payer key metrics, rolled up. Hygiene contribution and payer mix aggregated across the group, presented as a platform trend rather than practice by practice.
• Clinical compliance and the credentialing file, at scale. Maintaining licensure, credentialing, and clinical-compliance documentation across dozens or hundreds of providers is itself an operational proof point. Gaps here drive retrades and delay closings.

Underneath every one of those sits the legal architecture. A DSO operates around the corporate practice of dentistry doctrine, under which non-dentists generally may not own or control clinical decision-making, so the platform owns only the non-clinical management side through a management-services organization while licensed dentists own the professional corporations (Hendershot Cowart). That split has to be clean and consistently papered, and the doctrine varies substantially by state, with some states enforcing strictly and others permitting broad involvement. A buyer's counsel will test the MSO and professional-corporation structure across every state the platform operates in. A recap fails on the machine and on the structure, rarely on any single practice.

Who is in the room, and why can they never see each other?

A recap room holds parties who are competitors or adversaries in the same process, so isolation is the architecture rather than a setting you switch on. In one process you can have several competing sponsor bidders, a lender group underwriting the debt, a quality-of-earnings firm, legal counsel on multiple sides, and platform management. Put them in a shared drive and you have created a leak; the whole design problem is keeping them apart while they all read from the same underlying record.

The rules that make it work are three. First, competing bidders never see each other, not their documents, not their presence, not their pace. Watching engagement is real intelligence in a recap: which bidder is reading the payer analysis at 2 a.m. and which one has not opened the room in a week is a bid-seriousness signal the sponsor wants and the bidders must not have about each other. Per-party access lanes are what deliver that. Second, lenders see a different lane than equity bidders, because the credit group is underwriting debt capacity and covenants, not deciding what to bid for the equity. Third, the most competitively sensitive material is walled tighter than the room's NDA. Payer contract economics are the classic example: a bidder that is itself building a competing dental platform should never see another platform's negotiated payer rates, so that material goes into a clean-team lane that only cleared outside advisors, not the bidder's own operators, can open. This is the same discipline covered in our clean team data room guide, applied at platform scale.

Access is not only partitioned by party; it is revealed in stages as the process advances, which is the subject of the next section. The mechanics on any competent platform are per-party permission lanes, staged reveal, walled clean-team folders, and per-page audit trails so the sponsor can later prove exactly who saw what and when.

How does the room map to the recap process timeline?

The room grows lane by lane as the process moves through its phases, and it never opens all at once. A recap is a staged auction, and the data room is the staging mechanism. Here is the shape.

• Preparation and quality of earnings. Before anything goes to market, the sponsor and its quality-of-earnings firm assemble the platform evidence set: the vintage-cohort same-store analysis, the integration track record, the rolled-up KPIs, the credentialing and compliance file. This is the room in its private, pre-marketing state.
• First round, indications of interest. Screened bidders receive a confidential information memorandum and a teaser-level room with enough to submit an indication of interest, but not the crown-jewel detail. Many parties, shallow access.
• Second round, management presentations. Bidders who advance get management presentations and an expanded room with deeper financial and operational detail. Fewer parties, deeper access, and this is where the clean-team walls on payer economics matter most because the surviving bidders are the ones most likely to be competitors.
• Exclusivity and confirmatory diligence. The winning bidder signs a letter of intent, enters exclusivity, and runs confirmatory diligence against the full record while the losing bidders are shut out cleanly. As a reference band from the practice market, and hedged because platform processes typically run longer, signed letter of intent to close commonly runs 60 to 120 days (Dental Transitions).
• Close, then the reporting handoff. At close the room does not die. It changes jobs and becomes the home for the lender-reporting cadence, which is the next section.

The point of staging is control. A recap that dumps everything into one open room on day one has thrown away both its leverage and its confidentiality. Reveal by phase, and the room does the sequencing for you.

What does lender reporting look like after the recap?

It becomes a standing, recurring file-request workflow rather than a one-time deal room. A recapitalized DSO almost always carries a unitranche or syndicated facility, and the credit agreement turns the borrower into a monthly or quarterly reporter for the life of the loan. The obligations are consistent across facilities: covenant compliance certificates on the schedule the agreement sets, a borrowing base where the facility is asset-based, add-on notices and mini-diligence packs for each new acquisition drawn under the facility, and rolled-up KPI dashboards on same-store performance, payer mix, and provider headcount.

The wrong way to run this is email: the moment a compliance certificate travels as an attachment, the agent bank and a dozen syndicate members are reading different versions from different inboxes and the audit trail forks. The right way is a standing lender-reporting room where the agent and every syndicate member read from one permissioned source on a fixed cadence, the borrower posts each period's package once, and the credit teams pull what they need without pinging the CFO. Viewers are free on every Peony plan, so a full syndicate reading the reporting room adds nothing to the cost. The recap room simply carries the platform straight into this cadence, from proving the sale to servicing the debt, with no gap where reporting lives in someone's sent folder.

What does a recap data room cost?

On flat per-admin pricing the cost is set by how many people build the room, not by how many parties read it or how large the process is. This is the structural reason a recap belongs on flat pricing. A multi-party recap has, by design, a lot of readers: several bidding groups, a full lender syndicate, a quality-of-earnings firm, multiple counsel teams, and management. On any pricing model that charges per seat or per room, that reader count is a tax. On flat per-admin pricing it is free, because viewers are always free and only the admins who build the room are billed.

For a recap, the relevant Peony tier is Deal Team at 64 dollars per admin per month billed annually, with a four-admin minimum (or 89 dollars per admin monthly). A recap is administered by a group, the deal team, the CFO, and the sponsor's process leads, so the four-admin floor fits the shape of the work rather than fighting it. A four-admin team therefore runs about 3,072 dollars a year, a figure derived from the annual per-admin rate, and that single figure covers every lane in the process: bidders, lenders, the quality-of-earnings firm, counsel, and management, across as many rooms as the process needs.

The feature lines matter for a recap specifically. Per-viewer dynamic watermarking and Advanced NDA sit on the 52-dollar Data Room plan — that is what stamps a bidder's name across the payer analysis and gates the clean-team lane. One-click revoke and a Simple NDA are on the 30-dollar Business plan and up, which covers a lighter minority-raise process. Analytics and link expiry are on every tier, including the free plan, so the engagement intelligence that reads bid-seriousness is never behind a paywall. The free plan itself covers 50 documents, which is enough to test the workflow before committing.

One honest concession. When a very large, broadly syndicated platform sale is run by a bulge-bracket bank, the mandate frequently specifies an enterprise virtual-data-room incumbent, and for that one-off it is a rational venue with the support and scale a nine-figure auction expects. The flat plans are not trying to win that mandate. They win the economics a serial acquirer actually lives in: the many add-on rooms that built the platform, the recap process itself, and the years of lender reporting after, all on one subscription that does not re-price when you add a lane. Peony's 6,800+ customers include exactly this kind of repeat-process healthcare buyer. Broader market and vendor context lives in the healthcare data room guide, and for who funds these platforms in the first place, the independent sponsor healthcare capital partners directory is the route.

How this room differs from the others in the lane

One large multi-party recap room is a different thing than the many small add-on rooms that fed it. A roll-up runs many, small, serial diligence rooms, one per practice it acquires, each cloned from a reusable index and closed within weeks; that add-on program is the subject of our roll-up data room guide. A recap runs one, large, multi-party room that lives for the length of a staged auction and then converts into a lender-reporting home. The add-on rooms prove individual practices; the recap room proves the platform those practices became. If you are weighing an offer to join one of these platforms rather than running the recap, the DSO offer evaluation guide is written for you, and it explains why the rollover equity you take today is a claim on the recap described here.

The bottom line

A DSO recapitalization is the event the whole platform was built for, and it is not a bigger practice sale. It is an institutional buyer underwriting a machine: same-store growth by vintage, a real integration track record, provider retention, and a legal structure that holds up state by state. The room that runs it has to keep competing bidders, a lender group, a quality-of-earnings firm, and counsel apart while they all read from one record, reveal that record in stages, and then convert cleanly into the reporting home the credit agreement demands for years afterward. Run that on pricing that ignores how many parties are in the process, flat per-admin, unlimited rooms, free viewers, which is how Peony's 6,800+ customers get it, and the second bite costs the same to run as the first practice room ever did.

Frequently asked questions

What is a DSO recapitalization?

A DSO recapitalization is a platform-level capital event that resets the ownership of a dental support organization without selling the underlying practices. It takes three common shapes: a sponsor-to-sponsor majority sale, where one private-equity owner sells control to the next; a minority growth investment, where a new investor buys a stake alongside the existing owners; and a continuation structure, where the current sponsor moves the platform into a new vehicle and keeps running it. The rhythm is a three-to-seven-year hold, after which the sponsor recapitalizes or sells at, ideally, a higher multiple. That event is where the rollover equity selling dentists took in their practice acquisitions finally becomes liquid, which is why the industry calls it the second bite at the apple. Recent public examples, each as of its announcement date, include MB2 Dental's November 2024 recapitalization, in which Warburg Pincus invested about 525 million dollars as a new minority investor valuing the company around 3.5 billion dollars, and Affordable Care's June 2021 recapitalization of roughly 2.7 billion dollars.

How is a platform recap different from a single-practice sale?

The buyer is institutional and the diligence goes to the platform's machine, not one office's charts. A practice sale asks whether a single location's collections and patient base are real. A platform recap asks whether the group can keep compounding: same-store collections and EBITDA growth by acquisition vintage, the track record of integrating add-ons and realizing the synergies underwritten, de novo economics if the platform builds offices, provider retention and work-back status across the base, and a clean MSO and professional-corporation legal structure under the corporate practice of dentistry doctrine. Advisory bands for 2025 to 2026 put platform-grade DSO groups above 5 million dollars of EBITDA at roughly 10x to 12x or more, versus mid-single digits for a solo tuck-in. Buyers still sample individual practices, so a per-practice diligence layer still matters, but the value question is about the system.

What does a DSO platform have to prove in a recap?

It has to prove the machine works, at the platform level and by cohort. The core evidence set is same-store collections and EBITDA growth broken out by acquisition vintage, so a buyer can separate genuine organic growth from growth bought through acquisitions; an add-on integration track record that shows synergies realized against what was underwritten; a platform-level quality-of-earnings package with disciplined add-backs; de novo unit economics if the platform builds; provider retention and work-back commitment status across the base; hygiene and payer key metrics rolled up across the group; and clinical compliance plus a credentialing file maintained at scale. Underneath all of it sits the legal architecture: the management-services-organization and professional-corporation split has to be clean under the corporate practice of dentistry doctrine, which varies substantially by state. A recap fails on the machine, not on any one practice.

Who is in a recap data room, and why can they never see each other?

A recap room holds parties who are direct competitors or adversaries in the process, so isolation is the architecture, not a setting. In a single process you may have several competing sponsor bidders, a lender group underwriting the debt, a quality-of-earnings firm, legal counsel, and platform management. Competing bidders must never see each other's presence or pace, because who is reading what and how fast is bid-seriousness intelligence you do not want leaking. Lenders see a different lane than equity bidders. The most competitively sensitive material, such as payer contract economics, is walled into a clean-team lane that only cleared advisors, not the bidder's operators, can open. Access is granted per party and revealed in stages as the process moves from first round to confirmatory diligence, and every party reads from its own permissioned lane rather than a shared drive.

How does the data room map to the recap process timeline?

The room grows lane by lane as the process moves through its phases. In preparation the sponsor and its quality-of-earnings firm build the platform evidence set before anything goes to market. First-round bidders receive a confidential information memorandum and a teaser-level room and submit indications of interest. Second-round bidders who advance get management presentations and an expanded room. The winning bidder enters exclusivity and runs confirmatory diligence against the full record. As a reference band from the practice market, hedged because platform deals run longer, signed letter of intent to close commonly runs 60 to 120 days. After close the room does not die: it becomes the home for the lender-reporting cadence, holding the covenant certificates and add-on notices the credit agreement requires for the life of the facility.

What does lender reporting look like after a DSO recap?

It becomes a standing, recurring workflow rather than a one-time room. A recapitalized DSO usually carries a unitranche or syndicated facility, and the credit agreement obligates the borrower to deliver monthly or quarterly reporting packages: covenant compliance certificates, a borrowing base where the facility is asset-based, notices and mini-diligence packs for each new add-on acquisition, and rolled-up key-metric dashboards on same-store performance, payer mix, and provider headcount. Rather than emailing these to the agent bank and the syndicate deal by deal, the platform runs a permissioned reporting room where the agent and every syndicate member read from one source on a schedule. The room that hosted the recap simply changes jobs, from proving the sale to servicing the debt, and the reporting file-request workflow runs on the same cadence the agreement sets.

What does a DSO recapitalization data room cost?

On flat per-admin pricing the cost is set by how many people build the room, not by how large the process is or how many parties read it. Peony's Deal Team plan is 64 dollars per admin per month billed annually with a four-admin minimum, or 89 dollars per admin monthly, and it is the plan sized for a multi-party recap because the deal team, the CFO, and the sponsor's process leads all administer the room together. A four-admin team therefore runs about 3,072 dollars a year, a figure derived from the annual per-admin rate, and that covers every lane: bidders, lenders, the quality-of-earnings firm, counsel, and management. Viewers are always free, so a full syndicate and several bidding groups add nothing to the bill. Per-viewer watermarking and Advanced NDA sit on the 52-dollar Data Room plan; one-click revoke and Simple NDA are on the 30-dollar Business plan and up; analytics and link expiry are on every tier including the free plan. For a very large syndicated auction run by a bulge-bracket bank, an enterprise virtual-data-room incumbent is often the mandated venue, and that is a reasonable one-off spend; the flat plans win on the many-lane, repeat-process economics that a serial acquirer lives in.

What is the best data room for a DSO recapitalization?

The best data room for a DSO recap is one that runs several isolated parties in a single process, watermarks and gates the sensitive financials, and does not re-price every time you add a lane. That is the job Peony is built for, and I run it: per-party access lanes so competing bidders and the lender group never see each other, per-viewer dynamic watermarking and an Advanced NDA on the 52-dollar Data Room plan, one-click revoke and a Simple NDA on the 30-dollar Business plan, analytics and link expiry on every tier, and a free plan to test the workflow first. Viewers are always free and rooms are unlimited, so a multi-party recap costs the same as a single room. Peony serves 6,800+ customers across M&A, fundraising, and diligence. The honest concession: when a very large, syndicated platform sale is run by a bulge-bracket bank, the mandate frequently specifies an enterprise VDR incumbent, and for that one-off it is a rational venue. Plenty of sponsors run the recap and the ongoing lender reporting on Peony and accept the bank's platform for the largest processes.

Related resources

• Dental roll-up and DSO playbook — how the platform gets built, acquisition by acquisition; the journey this post exits
• DSO offer evaluation — the dentist's side, and why the rollover equity a seller takes rides on the recap described here
• Roll-up data room — the many small add-on rooms that feed the one large recap room
• Dental due diligence checklist — the per-practice layer buyers still sample inside a platform process
• Dental practice sale data room — the single-practice sale room, for comparison
• Quality of earnings — how buyers test adjusted EBITDA and how to prepare a platform-level package
• Clean team data room — walling the most competitively sensitive material, such as payer economics, from bidder operators
• Healthcare data room — the broader healthcare-diligence context and vendor landscape
• Independent sponsor healthcare capital partners — who funds these platforms and how deal-by-deal capital is raised